LANCASTER, Calif. / Mar 16, 2023 / Business Wire / Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that chief executive officer Shawn O’Connor will be presenting at the Sidoti Small-Cap Investor Conference taking place virtually on March 22-23, 2023.
Mr. O’Connor will be presenting on Thursday, March 23, 2023, at 3:15 p.m. Eastern Time. The live webcast may be accessed via this link and on the Investors page of the Simulations Plus website where it will also be available for replay after the event.
For more information about the Sidoti Small-Cap Investor Conference, please visit the conference website or contact Brian Siegel from Hayden IR at This email address is being protected from spambots. You need JavaScript enabled to view it..
About Simulations Plus
Serving clients worldwide for more than 25 years, Simulations Plus is a leading provider in the biosimulation market providing software and consulting services supporting drug discovery, development, research, and regulatory submissions. We offer solutions that bridge machine learning, physiologically based pharmacokinetics, quantitative systems pharmacology/toxicology, and population PK/PD modeling approaches. Our technology is licensed and applied by major pharmaceutical, biotechnology, and regulatory agencies worldwide. For more information, visit our website at www.simulations-plus.com. Follow us on Twitter | LinkedIn.
Environmental, Social, and Governance (ESG)
We focus our Environmental, Social, and Governance (ESG) efforts where we can have the most positive impact. To learn more about our latest initiatives and priorities, please visit our website to read our ESG Report
Last Trade: | US$12.87 |
Daily Change: | -0.04 -0.31 |
Daily Volume: | 759,093 |
Market Cap: | US$258.720M |
June 05, 2025 May 15, 2025 |
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORETerns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREEnd of content
No more pages to load